GTHX vs. XBI

Last updated Apr 2, 2026

Compare and contrast key facts about G1 Therapeutics, Inc. (GTHX) and SPDR S&P Biotech ETF (XBI).

XBI is a passively managed fund by State Street that tracks the performance of the S&P Biotechnology Select Industry Index. It was launched on Feb 6, 2006.

Performance

GTHX vs. XBI - Performance Comparison

The chart below illustrates the hypothetical performance of a $10,000 investment in G1 Therapeutics, Inc. (GTHX) and SPDR S&P Biotech ETF (XBI). The values are adjusted to include any dividend payments, if applicable.

GTHX vs. XBI - Yearly Performance Comparison

	2026 (YTD)	2025	2024	2023	2022	2021	2020	2019	2018	2017
GTHX G1 Therapeutics, Inc.	0.00%	0.00%	134.43%	-43.83%	-46.82%	-43.25%	-31.93%	38.02%	-3.48%	32.27%
XBI SPDR S&P Biotech ETF	5.43%	35.89%	1.01%	7.60%	-25.87%	-20.45%	48.33%	32.56%	-15.28%	24.07%

Returns By Period

GTHX

• 1D: —
• 1M: —
• YTD: —
• 6M: —
• 1Y: —
• 3Y*: —
• 5Y*: —
• 10Y*: —

XBI

• 1D: 0.64%
• 1M: 1.58%
• YTD: 5.43%
• 6M: 27.21%
• 1Y: 65.07%
• 3Y*: 19.25%
• 5Y*: -1.16%
• 10Y*: 9.39%

*Multi-year figures are annualized to reflect compound growth (CAGR)

Return for Risk

GTHX vs. XBI — Risk / Return Rank

Compare risk-adjusted metric ranks to identify better-performing investments over the past 12 months.

XBI

XBI Risk / Return Rank: 93
XBI Sharpe Ratio Rank: 93
XBI Sortino Ratio Rank: 94
XBI Omega Ratio Rank: 89
XBI Calmar Ratio Rank: 96
XBI Martin Ratio Rank: 95

The rank (0–100) shows how this investment's returns compare to the risk taken. Higher = better. Based on the past 12 months of data, combining Sharpe, Sortino, and other metrics used by quantitative funds and institutional investors.

GTHX vs. XBI - Risk-Adjusted Trends Comparison

This table presents a comparison of risk-adjusted performance metrics for G1 Therapeutics, Inc. (GTHX) and SPDR S&P Biotech ETF (XBI). Risk-adjusted metrics are performance indicators that assess an investment's returns in relation to its risk, enabling a more accurate comparison of different investment options.

Risk / return metrics aren't available yet — we need at least 12 months of trading data to calculate them.

Sharpe Ratios by Period

	GTHX	XBI	Difference
Sharpe Ratio (1Y) Calculated over the trailing 1-year period	—	2.28	—
Sharpe Ratio (5Y) Calculated over the trailing 5-year period	—	-0.04	—
Sharpe Ratio (10Y) Calculated over the trailing 10-year period	—	0.29	—
Sharpe Ratio (All Time) Calculated using the full available price history	—	0.36	—

Correlation

The correlation between GTHX and XBI is 0.49, which is considered to be moderate. This suggests that the two assets have some degree of positive relationship in their price movements. Moderate correlation can be acceptable for portfolio diversification, offering a balance between risk and potential returns.

Dividends

GTHX vs. XBI - Dividend Comparison

GTHX has not paid dividends to shareholders, while XBI's dividend yield for the trailing twelve months is around 0.34%.

	TTM	2025	2024	2023	2022	2021	2020	2019	2018	2017	2016	2015
GTHX G1 Therapeutics, Inc.	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
XBI SPDR S&P Biotech ETF	0.34%	0.37%	0.15%	0.02%	0.00%	0.04%	0.20%	0.00%	0.28%	0.24%	0.26%	0.61%

Drawdowns

Drawdown Indicators

	GTHX	XBI	Difference
Max Drawdown Largest peak-to-trough decline	—	-63.89%	—
Max Drawdown (1Y) Largest decline over 1 year	—	-13.39%	—
Max Drawdown (5Y) Largest decline over 5 years	—	-55.04%	—
Max Drawdown (10Y) Largest decline over 10 years	—	-63.89%	—
Current Drawdown Current decline from peak	—	-25.70%	—
Average Drawdown Average peak-to-trough decline	—	-20.91%	—
Ulcer Index Depth and duration of drawdowns from previous peaks	—	3.65%	—

Volatility

Volatility by Period

	GTHX	XBI	Difference
Volatility (1M) Calculated over the trailing 1-month period	—	11.31%	—
Volatility (6M) Calculated over the trailing 6-month period	—	19.25%	—
Volatility (1Y) Calculated over the trailing 1-year period	—	28.95%	—
Volatility (5Y) Calculated over the trailing 5-year period, annualized	—	32.23%	—
Volatility (10Y) Calculated over the trailing 10-year period, annualized	—	32.15%	—